With the continuous development of drug resistance in
bacteria
to traditional antibiotics, the demand for novel antibacterial agents
is urgent. Antimicrobial peptides (AMPs) are promising candidates
because of their unique mechanism of action and low tendency to induce
drug resistance. Previously, we cloned temporin-GHb (hereafter referred
to simply as “GHb”) from Hylarana guentheri. In this study, a series of derived peptides were designed, namely,
GHbR, GHbK, GHb3K, GHb11K, and GHbK4R. The five derived peptides had
stronger antibacterial activities against Staphylococcus aureus than the parent peptide GHb and could effectively inhibit the formation
of biofilms and eradicate mature biofilms in vitro. GHbR, GHbK, GHb3K,
and GHbK4R exerted bactericidal effects by disrupting membrane integrity.
However, GHb11K exhibited bacteriostatic efficacy with toroidal pore
formation on the cell membrane. In comparison to GHbK4R, GHb3K showed
much lower cytotoxicity against A549 alveolar epithelial cells, with
an IC50 > 200 μM, which was much higher than its
minimal inhibitory concentration (MIC = 3.1 μM) against S. aureus. The anti-infection potential of GHbK4R and GHb3K
was investigated in vivo. Compared with vancomycin, the two peptides
displayed significant efficacy in a mouse model of acute pneumonia
infected with S. aureus. Both GHbK4R and GHb3K also
had no obvious toxicity to normal mice after intraperitoneal administration
(15 mg/kg) for 8 days. Our results indicate that GHb3K and GHbK4R
might be promising candidates for the treatment of bacterial pneumonia
infected with S. aureus.